SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
J. Clin. Oncol 2022 Dec 15;[EPub Ahead of Print], MS Ahluwalia, DA Reardon, AP Abad, WT Curry, ET Wong, SA Figel, LL Mechtler, DM Peereboom, AD Hutson, HG Withers, S Liu, AN Belal, J Qiu, KM Mogensen, SS Dharma, A Dhawan, MT Birkemeier, DM Casucci, MJ Ciesielski, RA FenstermakerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.